rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SNDX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Syndax at UBS biopharma conference: growth, trials and competition
      Nov 17Investing.comSNDXUBS
      Syndax at Stifel 2026 Healthcare Conference: growth and pipeline push
      Nov 12Investing.comSNDXSF
      Syndax at Guggenheim healthcare conference: growth, expansion and risk
      Nov 10Investing.comSNDX
      Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
      Nov 9Yahoo FinanceSNDX
      Why Is Syndax Pharmaceuticals (SNDX) Drawing So Much ASH 2026 Attention?
      Nov 5Yahoo FinanceSNDX
      Syndax Pharmaceuticals Inc (SNDX) (Q3 2026) Earnings Call Highlights: Revenue Surges 82% as ...

      Syndax Pharmaceuticals Inc (SNDX) posted $83.3 million in Q3 2026 revenue, driven by strong demand for ReviForge and Niktimvo, while flagging a post-transplant revenue headwind and a CFO transition.

      Nov 5Yahoo FinanceSNDX
      Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
      Nov 4Yahoo FinanceSNDX
      Syndax Pharmaceuticals stock hits 52-week low at 12.79 USD
      Nov 4Investing.comSNDX
      Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is Key

      Syndax Pharmaceuticals shows strong Revuforj-driven growth, narrowing losses, and AML upside. Read the latest analysis on SNDX stock here.

      Nov 4Seeking AlphaSNDX
      Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
      Nov 4Yahoo FinanceSNDX
      Syndax Pharmaceuticals Stock Gains Focus After Revenue Growth And Pipeline Progress
      Nov 4Yahoo FinanceSNDX
      Syndax Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
      Nov 3Yahoo FinanceSNDX
      H.C. Wainwright lowers Syndax Pharmaceuticals price target to $36
      Nov 3Investing.comSNDX
      Mizuho reiterates Outperform on Syndax stock, $43 target
      Nov 3Investing.comSNDX
      Syndax Pharmaceuticals (SNDX) Stock May Be Rich After Revuforj Award Win

      Syndax Pharmaceuticals has had a rough run in 2026, and the mixed headlines around its pipeline now put fresh attention on what investors are paying for its current level of sales. The question is whether that recent share price slide still lines up with what the business generates in revenue today. The stock is down about 38.5% year to date, which puts extra weight on the issue of whether today's valuation can still be explained by its sales base. Revuforj winning a major Prix Galien USA...

      Nov 3Yahoo FinanceSNDX
      Syndax Pharmaceuticals (SNDX) Missed On Q3 Results, Is The 65% Undervaluation Case Still Intact?

      Why Syndax Pharmaceuticals Stock Is Back in Focus After Q3 Results Syndax Pharmaceuticals (SNDX) moved into the spotlight after reporting third quarter 2026 results, with revenue of US$83.3 million and a net loss of US$49.43 million from continuing operations. The earnings miss and CFO transition have come against a weaker tape, with Syndax Pharmaceuticals’ share price down 25.57% over the past month and 31.34% over 90 days, while the 1 year total shareholder return has declined 4.80%. This...

      Nov 3Yahoo FinanceSNDX
      Syndax: Q3 Earnings Snapshot
      Nov 3Yahoo FinanceSNDX
      What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call
      Nov 3Yahoo FinanceSNDX
      Syndax Q3 2026 slides: dual-drug growth, path to profitability
      Nov 2Investing.comSNDX
      Earnings call transcript: Syndax beats revenue but misses EPS in Q3 2026
      Nov 2Investing.comSNDX
      Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates
      Nov 2Yahoo FinanceSNDX
      Syndax Pharmaceuticals earnings missed by $0.07, revenue topped estimates
      Nov 2Investing.comSNDX
      Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 2Yahoo FinanceSNDX
      Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
      Nov 2Yahoo FinanceSNDX
      Syndax Pharmaceuticals director Dennis Podlesak sells $113,716 in stock
      Oct 30Investing.comSNDX
      Syndax Announces Participation in November Investor Conferences
      Oct 30Yahoo FinanceSNDX
      Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
      Oct 26Yahoo FinanceSNDX
      Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
      Oct 26Yahoo FinanceSNDX
      Syndax Pharmaceuticals stock hits 52-week low at 12.98 USD
      Oct 16Investing.comSNDX
      Syndax Revuforj: The Best Inventions of 2026

      Find out why Syndax Revuforj is on TIME's list of 2026's best inventions.

      Oct 15TimeSNDX
      Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
      Oct 15Yahoo FinanceSNDX
      Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

      SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.

      Oct 14Yahoo FinanceSNDX
      Syndax Pharmaceuticals Suffers Pipeline Blow - Syndax Pharmaceuticals (NASDAQ:SNDX)

      Syndax Pharmaceuticals halts axatilimab in idiopathic pulmonary fibrosis after the candidate misses the primary endpoint in a Phase 2 trial.

      Oct 13BenzingaSNDX
      Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans.
      Oct 13Barron'sSNDX
      Syndax Pharmaceuticals Selloff After IPF Trial Failure Appears 'Overdone,' BofA Securities Says
      Oct 13Yahoo FinanceSNDX
      Stifel maintains Syndax stock rating after trial failure
      Oct 13Investing.comSNDX
      Why is Syndax Pharmaceuticals stock sliding today?
      Oct 13Investing.comSNDX
      BofA Securities Adjusts Syndax Pharmaceuticals PT to $23 From $26, Maintains Buy Rating
      Oct 13Yahoo FinanceSNDX
      Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Sessi

      U.S. futures mixed; Syndax plunged 17% after its lung fibrosis trial missed its endpoint. Zhibao, Chaince, Six Flags and tech stocks also fell premarket.

      Oct 13BenzingaBNTXSNDXSTX
      Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed?
      Oct 13Yahoo FinanceSNDX
      Syndax Pharmaceuticals' Axatilimab Trial in Pulmonary Fibrosis Misses Primary Endpoint
      Oct 12Yahoo FinanceSNDX
      Syndax’s axatilimab fails primary endpoint in pulmonary fibrosis trial
      Oct 12Investing.comSNDX
      Syndax Pharmaceuticals stock tumbles on failed IPF trial
      Oct 12Investing.comSNDX
      H.C. Wainwright reiterates Buy on Syndax stock, $38 target
      Oct 12Investing.comSNDX
      Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
      Oct 12ReutersSNDX
      Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2026, the Company granted inducement awards to purchase up to 213,300 shares of common stock to nine new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencemen

      Oct 2Yahoo FinanceSNDX
      H.C. Wainwright reiterates Syndax stock Buy rating at $38 target
      Oct 1Investing.comSNDX
      Jefferies reiterates Buy on Syndax stock ahead of IPF data
      Sep 29Investing.comSNDXJEF
      Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases (SNDX)

      Syndax achieved FDA approval for Revuforj in r/r mNPM1 AML and is pursuing pivotal studies to expand into 1st-line AML populations. Read why SNDX is a Strong Buy.

      Sep 28Seeking AlphaSNDX
      Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts (NASDAQ:SNDX)

      Syndax Pharmaceuticals, Inc. has an attractive valuation, key readouts in Q4, and an expanding pipeline. Read more on SNDX stock here.

      Sep 25Seeking AlphaSNDX

      This is the newest page. Registered accounts read further back.